A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of Escalating Doses of AGS62P1 Given as Monotherapy in Subjects with Acute Myeloid Leukemia (AML)
The goals of this clinical research study are to find the highest tolerable dose of AGS62P1 that can be given to patients with acute myeloid leukemia (AML) that is relapsed (has come back) or is resistant to therapy to learn if the highest tolerable dose of AGS62P1 can help to control AML and to compare 2 different dosing schedules of the study drug. The safety of AGS62P1 will also be studied. This is the first study using AGS62P1 in humans.
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: AGS62P1
Treatment Location: Both at MDACC & and Other Sites
Sponsor: Agensys, Inc.
IRB Review and Approval Date: 04/14/2017
Recruitment Status: Open
Projected Accrual: 100
Information and next steps
Malignant neoplasms stated as primary lymphoid haematopoietic
For general questions about clinical trials: